This is a preview of subscription content, log in via an institution to check access.
References
1. Bensimon AG, et al. Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma. 2020 Genitourinary Cancers Symposium : abstr. 716, 13 Feb 2020. Available from: URL: https://meetinglibrary.asco.org/record/183714/abstract
2. De Mello RA, et al. Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. Perspective. 2020 Genitourinary Cancers Symposium : abstr. 689, 13 Feb 2020. Available from: URL: https://meetinglibrary.asco.org/record/183690/abstract
Rights and permissions
About this article
Cite this article
Cost effective therapy for advanced RCC: avelumab or pembrolizumab?. PharmacoEcon Outcomes News 850, 14 (2020). https://doi.org/10.1007/s40274-020-6702-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6702-z